1
人8異前列腺素F2α（8-iso-PGF2a）ELISA kit 人8異前列腺素F2α ELISA試劑盒 Human 8-iso prostaglandin F2α
（8-iso-PGF2α） ELISA Kit
（96 T）
l This immunoassay kit allows for the in vitro quantitative determination of human
8-iso-PGF2α concentrations in serum, plasma and other biological fluids.
l Expiration date six months from the date of manufacture
l FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.
2
INTRODUCTION
Isoprostanes are a newly-described group of prostaglandin-like
compounds which can be produced independently of the
cyclooxygenase pathway. Isoprostanes are formed under
conditions of oxidant stress through a free radical action on
arachidonic acid in cell membranes and are subsequently
cleaved, presumably by the action of phospholipase enzymes.
Free and estered F2 isoprostanes are amongst the more
abundant forms with in vivo levels ranging between 5 and 166
pg/ml in normal human plasma. In addition, in man plasma F2
isoprostane levels increase with age and are elevated in
smokers, possibly due to oxidants found incigarette smoke.
Further, 8-iso PGF2a specically, is increased approximay
three fold in individuals with non-insulin dependent diabetes
mellitus, a disease state associated with endothelial dysfunction
and oxidative damage.
The biological signicance of isoprostane formation is not
compley understood. Nevertheless, evidence increasingly
suggests that isoprostanes have important contractile effects on
3
smooth muscle function. Indeed, 8-iso PGF2a has been shown
to cause contraction of a variety of smooth muscle preparations
including human myometrium, guinea-pig and human airways,
rat renal and pulmonary vessels and rabbit pulmonary vessels.
Where tested, the contractile actions of 8-iso PGF2a are blocked
by thromboxane receptor （TP） antagonists. 8-Iso PGF2a also
causes plaet aggregation, possibly via TP receptor activation,
although evidence suggests that specic isoprostane receptors
may be present in some preparations. In contrast to the
contractile actions of 8-iso PGF2a, the putative dilator properties
of 8-iso PGF2a have not been investigated.
PRINCIPLE OF THE ASSAY
The microtiter plate provided in this kit has been pre-coated with
an antibody specific to 8-iso-PGF2α. Standards or samples are
then added to the appropriate microtiter plate wells with a
biotin-conjugated antibody preparation specific for 8-iso-PGF2α
and Avidin conjugated to Horseradish Peroxidase （HRP） is
added to each microplate well and incubated. Then a TMB
4
（3,3',5,5' tetramethyl-benzidine） substrate solution is added to
each well. Only those wells that contain 8-iso-PGF2α,
biotin-conjugated antibody and enzyme-conjugated Avidin will
exhibit a change in color. The enzyme-substrate reaction is
terminated by the addition of a sulphuric acid solution and the
color change is measured spectrophotometrically at a
wavelength of 450 nm ± 2 nm. The concentration of 8-iso-PGF2α
in the samples is then determined by comparing the O.D. of the
samples to the standard curve.
DETECTION RANGE
78 pg/ml-5000 pg/ml. The standard curve concentrations used
for the ELISA’s were 5000 pg/ml, 2500 pg/ml, 1250 pg/ml, 625
pg/ml, 312 pg/ml, 156 pg/ml, 78 pg/ml.
SPECIFICITY
This assay recognizes recombinant and natural human
8-iso-PGF2α. No significant cross-reactivity or interference was
observed.
5
SENSITIVITY
The minimum detectable dose of human 8-iso-PGF2α is typically
less than 20 pg/ml.
The sensitivity of this assay, or Lower Limit of Detection （LLD）
was defined as the lowest protein concentration that could be
differentiated from zero.
MATERIALS PROVIDED
Reagent Quantity
Assay plate 1
Standard 2
Sample Diluent 1 x 20 ml
Biotin-antibody Diluent 1 x 10 ml
HRP-avidin Diluent 1 x 10 ml
Biotin-antibody 1 x 120μl
HRP-avidin 1 x 120μl
Wash Buffer
1 x 20 ml
（25×concentrate）
TMB Substrate 1 x 10 ml
Stop Solution 1 x 10 ml
6
STORAGE
1. Unopened test kits should be stored at 2-8°C upon receipt
and the microtiter plate should be kept in a sealed bag. The
test kit may be used throughout the expiration date of the kit,
provided it is stored as prescribed above. Refer to the
package label for the expiration date.
2. Opened test plate should be stored at 2-8°C in the aluminum
foil bag with desiccants to minimize exposure to damp air. The
kits will remain stable until the expiring date shown, provided it
is stored as prescribed above.
3. A microtiter plate reader with a bandwidth of 10 nm or less
and an optical density range of 0-3 OD or greater at 450nm
wavelength is acceptable for use in absorbance
measurement.
REAGENT PREPARATION
Bring all reagents to room temperature before use.
1. Wash Buffer If crystals have formed in the concentrate,
warm up to room temperature and mix gently until the
crystals have compley dissolved. Dilute 20 ml of Wash
Buffer Concentrate into deionized or distilled water to prepare
500 ml of Wash Buffer.
7
2. Standard Centrifuge the standard vial at 6000-10000rpm
for 30s. Reconstitute the Standard with 1.0 ml of Sample
Diluent. This reconstitution produces a stock solution of 5000
pg/ml. Allow the standard to sit for a minimum of 15 minutes
with gentle agitation prior to making serial dilutions. The
undiluted standard serves as the high standard （5000 pg/ml）.
The Sample Diluent serves as the zero standard （0 pg/ml）.
Prepare fresh for each assay. Use within 4 hours and discard
after use.
3. Biotin-antibody Centrifuge the vial before opening. Dilute
to the working concentration using Biotin-antibody
Diluent（1:100）, respectively.
4. HRP-avidin Centrifuge the vial before opening. Dilute to the
working concentration using HRP-avidin Diluent（1:100）,
respectively.
Precaution: The Stop Solution provided with this kit is an acid solution. Wear
eye, hand, face, and clothing protection when using this material.
OTHER SUPPLIES REQUIRED
? Microplate reader capable of measuring absorbance at 450
nm, with the correction wavelength set at 540 nm or 570 nm.
8
? Pipettes and pipette tips.
? Deionized or distilled water.
? Squirt bottle, manifold dispenser, or automated microplate
washer.
? An incubator which can provide stable incubation conditions
up to 37°C±0.5°C.
SAMPLE COLLECTION AND STORAGE
l Serum Use a serum separator tube （SST） and allow
samples to clot for 30 minutes before centrifugation for 15
minutes at 1000 g. Remove serum and assay immediay or
aliquot and store samples at -20°C. Centrifuge the sample
again after thawing before the assay. Avoid repeated
freeze-thaw cycles.
l Plasma Collect plasma using citrate, EDTA, or heparin as
an anticoagulant. Centrifuge for 15 minutes at 1000 g within
30 minutes of collection. Assay immediay or aliquot and
store samples at -20°C. Centrifuge the sample again after
thawing before the assay. Avoid repeated freeze-thaw cycles.
Note: Grossly hemolyzed samples are not suitable for use in this assay.
9
ASSAY PROCEDURE
Bring all reagents and samples to room temperature before use. It is
recommended that all samples, standards, and controls be assayed in duplicate.
All the reagents should be added directly to the liquid level in the well. The
pipette should avoid contacting the inner wall of the well.
1. Add 100μl of Standard, Blank, or Sample per well. Cover with
the adhesive strip. Incubate for 2 hours at 37°C.
2. Remove the liquid of each well, don’t wash.
3. Add 100μl of Biotin-antibody working solution to each well.
Incubate for 1 hour at 37°C. Biotin-antibody working
solution may appear cloudy. Warm up to room temperature
and mix gently until solution appears uniform.
4. Aspirate each well and wash, repeating the process three
times for a total of three washes. Wash: Fill each well with
Wash Buffer （200μl） and let it stand for 2 minutes, then
remove the liquid by flicking the plate over a sink. The
remaining drops are removed by patting the plate on a paper
towel. Complete removal of liquid at each step is essential to
good performance.
1 0
5. Add 100μl of HRP-avidin working solution to each well.
Cover the microtiter plate with a new adhesive strip. Incubate
for 1 hour at 37°C.
6. Repeat the aspiration and wash five times as step 4.
7. Add 90μl of TMB Substrate to each well. Incubate for 10-30
minutes at 37°C. Keeping the plate away from drafts and
other temperature fluctuations in the dark.
8. Add 50μl of Stop Solution to each well when the first four
wells containing the highest concentration of standards
develop obvious blue color. If color change does not appear
uniform, gently tap the plate to ensure thorough mixing.
9. Determine the optical density of each well within 30 minutes,
using a microplate reader set to 450 nm.
CALCULATION OF RESULTS
Using the professional soft "Curve Exert 1.3" to make a standard curve is
recommended, which can be downloaded from our web.
Average the duplicate readings for each standard, control, and
sample and subtract the average zero standard optical density.
Create a standard curve by reducing the data using computer
software capable of generating a four parameter logistic （4-PL）
1 1
curve-fit. As an alternative, construct a standard curve by plotting
the mean absorbance for each standard on the y-axis against
the concentration on the x-axis and draw a best fit curve through
the points on the graph. The data may be linearized by plotting
the log of the 8-iso-PGF2α concentrations versus the log of the
O.D. and the best fit line can be determined by regression
analysis. This procedure will produce an adequate but less
precise fit of the data. If samples have been diluted, the
concentration read from the standard curve must be multiplied by
the dilution factor.
LIMITATIONS OF THE PROCEDURE
? The kit should not be used beyond the expiration date on the
kit label.
? Do not mix or substitute reagents with those from other lots or
sources.
? It is important that the Standard Diluent selected for the
standard curve be consistent with the samples being
assayed.
? If samples generate values higher than the highest standard,
dilute the samples with the appropriate Standard Diluent and
repeat the assay.
1 2
? Any variation in Standard Diluent, operator, pipetting
technique, washing technique, incubation time or
temperature, and kit age can cause variation in binding.
? This assay is designed to eliminate interference by soluble
receptors, binding proteins, and other factors present in
biological samples. Until all factors have been tested in the
Immunoassay, the possibility of interference cannot be
excluded.
TECHNICAL HINTS
? Centrifuge vials before opening to collect contents.
? When mixing or reconstituting protein solutions, always avoid
foaming.
? To avoid cross-contamination, change pipette tips between
additions of each standard level, between sample additions,
and between reagent additions. Also, use separate reservoirs
for each reagent.
? When using an automated plate washer, adding a 30 second
soak period following the addition of wash buffer, and/or
rotating the plate 180 degrees between wash steps may
improve assay precision.
1 3
? To ensure accurate results, proper adhesion of plate sealers
during incubation steps is necessary.
? Substrate Solution should remain colorless or light blue until
added to the plate. Keep Substrate Solution protected from
light. Substrate Solution should change from colorless or light
blue to gradations of blue.
? Stop Solution should be added to the plate in the same order
as the Substrate Solution. The color developed in the wells
will turn from blue to yellow upon addition of the Stop Solution.
Wells that are green in color indicate that the Stop Solution
has not mixed thoroughly with the Substrate Solution.